Contineum Therapeutics, Inc. Class A Common Stock (CTNM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has a cash flow conversion efficiency ratio of -0.048x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.50 Million) by net assets ($239.66 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see CTNM stock market capitalisation for the company's overall valuation and market capitalisation.
Contineum Therapeutics, Inc. Class A Common Stock - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Contineum Therapeutics, Inc. Class A Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Contineum Therapeutics, Inc. Class A Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Contineum Therapeutics, Inc. Class A Common Stock ranked by their cash flow conversion efficiency. Explore earnings quality score of Contineum Therapeutics, Inc. Class A Com to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Liuzhou Liangmianzhen Co Ltd
SHG:600249
|
0.003x |
|
Xinjiang Talimu Agriculture Development Co Ltd
SHG:600359
|
-0.010x |
|
Hyundai Bioscience Co. Ltd
KQ:048410
|
-0.018x |
|
Sino-Argi Leading Biosciences
SHG:603970
|
-0.219x |
|
Plastika Kritis S.A.
AT:PLAKR
|
0.019x |
|
Actron Technology
TWO:8255
|
0.039x |
|
Taiwan Navigation Co Ltd
TW:2617
|
0.046x |
|
Hibiscus Petroleum BHD
KLSE:5199
|
-0.186x |
Annual Cash Flow Conversion Efficiency for Contineum Therapeutics, Inc. Class A Common Stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of Contineum Therapeutics, Inc. Class A Common Stock from 2021 to 2025. View Contineum Therapeutics, Inc. Class A Com (CTNM) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $260.99 Million | $-55.31 Million | -0.212x | -27.80% |
| 2024-12-31 | $198.07 Million | $-32.84 Million | -0.166x | +41.78% |
| 2023-12-31 | $-67.94 Million | $19.35 Million | -0.285x | +44.41% |
| 2022-12-31 | $39.27 Million | $-20.12 Million | -0.512x | -20.14% |
| 2021-12-31 | $61.59 Million | $-26.27 Million | -0.426x | -- |
About Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibr… Read more